Compare Eaton Corporation plc (ETN) vs GSK plc (GSK) Price & Performance

Eaton Corporation (ETN) trades at $404.20, down 2.72% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.81 exceeding expectations. Analyst consensus is overwhelmingly positive with 25 buy ratings and a $449.50 price target. Recent news highlights growth in AI data center power infrastructure and a new sustainability report showing 40% emissions reduction.

ETN's outlook remains favorable due to robust demand in data center and aerospace markets, though elevated valuation multiples (P/E 40.4) pose a risk if growth moderates. The stock offers upside to consensus targets but faces execution risks from large 2026 investing outflows. Dividend payments provide income support with the next $1.10 distribution scheduled for May 29, 2026.

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.